The MORE trial: effectiveness of adapalene gel 0.1% in real-world dermatology practices

Effective treatment of acne often involves combination therapy. Topical retinoids are effective when used in combination with topical and/or oral antibiotics, and recent guidelines from the Global Alliance to Improve Outcomes in Acne recommend retinoids as part of initial and maintenance therapies. The Measuring Acne Outcomes in a Real-World Experience (MORE) trial evaluated the effectiveness, tolerability, and acceptability of adapalene gel 0.1% in combination with other acne treatments for subjects with moderate to moderately severe acne, either as an initial combination regimen for subjects not treated at baseline or as add-on therapy for patients already treated for acne. Of 1979 subjects aged 12 years or older who were enrolled, 1662 completed the 12-week assessment using adapalene gel 0.1% once daily for 12 weeks according to protocol. Adherence to therapy was high for both the initial combination and add-on therapies with adapalene gel 0.1%. Significant reductions in acne lesions were seen as early as week 6 and were even more pronounced by week 12 (P < .001 vs baseline for all lesion types at both weeks 6 and 12). A majority of investigators rated adapalene gel 0.1% superior to other acne treatments they had prescribed, and the success rate also was high based on the Investigator Global Assessment. The MORE trial confirms that adapalene gel 0.1% is effective in clearing both inflammatory and noninflammatory acne lesions in patients with moderate to moderately severe acne.